SCHEMBL3250490

SCHEMBL3250490

Cc1cc(C)cc(S(=O)(=O)N(Cc2nnnn2C)c2ccc(Cl)cc2Cc2c(F)cccc2F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 2/20 0.40
CCR2 P41597 2/20 0.40
CCR4 P51679 2/20 0.40
PTGER1 P34995 8/20 0.38
MAPT P10636 1/20 0.34
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
PGR P06401 1/20 0.33
POLB P06746 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
ALDH1A1 P00352 2/20 0.32
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3255923 0.92 PTGER1 (0.37) CCR1CCR2CCR4PTGER1CNR1
SCHEMBL3244840 0.86 PKM (0.41) CCR1CCR2CCR4MAPTPOLB
SCHEMBL3253516 0.84 PTGER1 (0.38) PTGER1CNR1CNR2POLBMCOLN3
SCHEMBL3252340 0.81 PTGER1 (0.37) PTGER1CNR1CNR2POLBMCOLN3
SCHEMBL3251397 0.78 PKM (0.40) CCR1CCR2CCR4MAPTPOLB
SCHEMBL3253907 0.78 PTGER1 (0.42) CCR1CCR2CCR4PTGER1PGR
SCHEMBL3252902 0.77 HPGD (0.40) PTGER1MAPTPOLBMCOLN3MEN1
SCHEMBL13357747 0.77 PTGER1 (0.44) PTGER1MAPTPOLBMCOLN3MEN1
SCHEMBL8275141 0.76 CCR1 (0.34) CCR1CCR2CCR4POLBMCOLN3
SCHEMBL14441489 0.73 MCOLN2 (0.32) CCR1CCR2CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 CCR1 1441/4885CCR2 829/4885CCR4 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.